Abstract
The deregulated cell cycle is a prominent hallmark of oncogenesis. In addition to the genetic alterations in G1 and S phase, emerging data demonstrate that the loss of checkpoint control at the G2/M transition is also closely involved in neoplastic transformation. Among many modulators of the G2/M transition, the defective regulation of cyclin B1, the regulatory subunit of cyclin dependent kinase 1 (Cdk1), and of Polo-like kinase 1 (Plk1) is attracting increasing attention as both of them are overexpressed in a wide spectrum of human tumors. Cyclin B1 and Plk1 serve as negative prognostic markers for patients with various tumors. In this review, we focus on these two molecules and highlight their roles in normal cell cycle, the involvement in oncogenesis and their potential as intervention targets for antitumor therapy.
Keywords: g/m transition, polo-like kinase, cdk/cyclin b, inhibition of proliferation, apoptosis
Letters in Drug Design & Discovery
Title: Targeting the G2/M Transition for Antitumor Therapy
Volume: 2 Issue: 4
Author(s): J. Yuan and K. Strebhardt
Affiliation:
Keywords: g/m transition, polo-like kinase, cdk/cyclin b, inhibition of proliferation, apoptosis
Abstract: The deregulated cell cycle is a prominent hallmark of oncogenesis. In addition to the genetic alterations in G1 and S phase, emerging data demonstrate that the loss of checkpoint control at the G2/M transition is also closely involved in neoplastic transformation. Among many modulators of the G2/M transition, the defective regulation of cyclin B1, the regulatory subunit of cyclin dependent kinase 1 (Cdk1), and of Polo-like kinase 1 (Plk1) is attracting increasing attention as both of them are overexpressed in a wide spectrum of human tumors. Cyclin B1 and Plk1 serve as negative prognostic markers for patients with various tumors. In this review, we focus on these two molecules and highlight their roles in normal cell cycle, the involvement in oncogenesis and their potential as intervention targets for antitumor therapy.
Export Options
About this article
Cite this article as:
Yuan J. and Strebhardt K., Targeting the G2/M Transition for Antitumor Therapy, Letters in Drug Design & Discovery 2005; 2 (4) . https://dx.doi.org/10.2174/1570180054038378
DOI https://dx.doi.org/10.2174/1570180054038378 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Vasoactive Intestinal Peptide (VIP): Historic Perspective and Future Potential]
Endocrine, Metabolic & Immune Disorders - Drug Targets Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer
Current Pharmaceutical Biotechnology Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery Follicular Immunology Environment and the Influence on In Vitro Fertilization Outcome
Current Women`s Health Reviews ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Letters in Drug Design & Discovery Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo
CNS & Neurological Disorders - Drug Targets Role of Tyrosine Phosphatase Inhibitors in Cancer Treatment with Emphasis on SH2 Domain-Containing Tyrosine Phosphatases (SHPs)
Anti-Cancer Agents in Medicinal Chemistry Clinical Pharmacogenomics of Thiopurine S-methyltransferase
Current Clinical Pharmacology NBS1 Heterozygosity and Cancer Risk
Current Genomics Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design Rho-Signaling Pathways in Chronic Myelogenous Leukemia
Cardiovascular & Hematological Disorders-Drug Targets New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery